Edition:
United States

Teva Pharmaceutical Industries Ltd (TEVA.N)

TEVA.N on New York Stock Exchange

17.82USD
20 Apr 2018
Change (% chg)

$0.11 (+0.62%)
Prev Close
$17.71
Open
$17.85
Day's High
$17.99
Day's Low
$17.72
Volume
2,010,628
Avg. Vol
3,430,348
52-wk High
$33.82
52-wk Low
$10.85

Select another date:

Thu, Apr 19 2018

BRIEF-Paxman Receives Market Approval In Mexico

* PAXMAN RECEIVES MARKET APPROVAL IN MEXICO AND PLANS Q2 LAUNCH WITH LICENSE PARTNER TEVA PHARMACEUTICAL INDUSTRIES LTD

BRIEF-Teva And P&G Have Agreed To Terminate The PGT Healthcare Partnership

* TEVA AND THE PROCTER & GAMBLE COMPANY HAVE AGREED TO TERMINATE THE PGT HEALTHCARE PARTNERSHIP

UPDATE 1-Israeli unions warn Teva Pharm over plan to close Ashdod plant

JERUSALEM, April 15 Israel's main labour federation intends to strike or take legal action against Teva Pharmaceutical Industries if the drugmaker does not suspend a decision to close a plant in the port city of Ashdod, it said on Sunday.

Israeli unions warn Teva Pharm over plan to close Ashdod plant

JERUSALEM Israel's main labor federation intends to take labor or legal action against Teva Pharmaceutical Industries if the drugmaker does not suspend a decision to close a plant in the Israeli port city of Ashdod, it said on Sunday.

Israeli unions warn Teva Pharm over plan to close Ashdod plant

JERUSALEM, April 15 Israel's main labour federation intends to take labour or legal action against Teva Pharmaceutical Industries if the drugmaker does not suspend a decision to close a plant in the Israeli port city of Ashdod, it said on Sunday.

Teva Pharm to close plant in Israel after no buyer found

JERUSALEM Debt-laden Teva Pharmaceutical Industries said on Monday it would close an unprofitable plant in the Israeli port city of Ashdod in March 2019 after failing to find a buyer for the facility.

Teva Pharm to close plant in Israel after no buyer found

JERUSALEM, April 9 Debt-laden Teva Pharmaceutical Industries said on Monday it would close an unprofitable plant in the Israeli port city of Ashdod in March 2019 after failing to find a buyer for the facility.

Teva wins reversal of U.S. jury's $235 million GSK drug patent verdict

A federal judge on Wednesday overturned a U.S. jury's verdict that required Teva Pharmaceutical Industries Ltd to pay GlaxoSmithKline Plc more than $235 million for infringing a patent covering its blood pressure drug Coreg.

CORRECTED-UPDATE 2-Teva wins reversal of U.S. jury's $235 mln GSK drug patent verdict

March 28 A federal judge on Wednesday overturned a U.S. jury's verdict that required Teva Pharmaceutical Industries Ltd to pay GlaxoSmithKline Plc more than $235 million for infringing a patent covering its blood pressure drug Coreg.

Teva wins reversal of U.S. jury's $235 mln GSK drug patent verdict

March 28 A federal judge on Wednesday overturned a U.S. jury's verdict that required Teva Pharmaceutical Industries Ltd to pay GlaxoSmithKline Plc more than $235 million for infringing a patent covering its blood pressure drug Coreg.

Select another date: